NATCOPHARM IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| ₹ CR · FY | FY22 | FY23 | FY24 | FY25 | FY26 | Sep'26 | YOY |
|---|---|---|---|---|---|---|---|
| Profit & loss | |||||||
| Revenue | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 | — | — |
| Operating profit | 264 | 936 | 1,754 | 2,196 | 1,462 | — | — |
| OPM % | 13.6% | 34.6% | 43.9% | 49.6% | 35.9% | — | |
| Interest | 18 | 14 | 19 | 24 | 37 | — | — |
| Profit before tax | 202 | 862 | 1,674 | 2,291 | 1,491 | — | — |
| Net profit | 170 | 715 | 1,388 | 1,883 | 1,418 | — | — |
| NPM % | 8.7% | 26.4% | 34.7% | 42.5% | 34.8% | — | |
| Balance sheet & cash | |||||||
| Total assets | 5,109 | 5,657 | 6,906 | 8,631 | 11,074 | 11,799 | +6.5% |
| Equity | 4,263 | 4,873 | 5,853 | 7,607 | 9,221 | 9,765 | +5.9% |
| Debt | 416 | 167 | 371 | 279 | 714 | 1,033 | +44.7% |
| Cash from ops | 46 | 849 | 1,212 | 1,697 | 1,768 | — | — |
| Capex | — | — | — | — | — | — | — |
| CHECK | RESULT | VALUE |
|---|---|---|
| Net profit positive | n/a | — |
| Operating cash flow positive | n/a | — |
| ROA improved | n/a | 12.8% → — |
| Cash from ops > net profit | n/a | — |
| Leverage fell | ✗ FAIL | 0.06 → 0.09 |
| Current ratio improved | n/a | — → — |
| Gross margin improved | n/a | 35.9% → — |
| Asset turnover improved | n/a | 0.37 → — |
| Interest cover above 3× | n/a | — |
| ₹ CR · QUARTER | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | YOY |
|---|---|---|---|---|---|---|---|---|---|
| Profit & loss | |||||||||
| Revenue | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 | 967 | −29.1% |
| Operating profit | 39 | 548 | 571 | 579 | 159 | 128 | 186 | 258 | −55.4% |
| OPM % | 8.2% | 44.9% | 43.0% | 42.5% | 24.6% | 17.3% | 25.3% | 26.7% | |
| Interest | 4 | 10 | 3 | 13 | 10 | 11 | 13 | 18 | +38.5% |
| Profit before tax | 164 | 506 | 572 | 614 | 161 | 144 | 186 | 243 | −60.4% |
| Net profit | 132 | 406 | 480 | 518 | 151 | 269 | 206 | 203 | −60.8% |
| NPM % | 27.8% | 33.3% | 36.1% | 38.0% | 23.3% | 36.4% | 28.0% | 21.0% |